Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biovertis AG

www.biovertis.com

Latest From Biovertis AG

War on C Difficile Is Being Fought On Multiple Fronts

Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.

Infectious Diseases Research & Development

Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns

Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.
Business Strategies Deals

TVM Raises White Flag On Biovertis & Morphochem

Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4% stake worth €900,000. Since their formation, Biovertis and Morphochem have had more than $96m invested in them.

Commercial M & A

Deals Shaping the Medical Industry (1/06)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Bioventis AG
  • Bioventis - Information-driven drug design AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Austria
  • Parent & Subsidiaries
  • Biovertis AG
  • Senior Management
  • Erich Felber, CEO
    Uwe von Ahsen, PhD, CSO
  • Contact Info
  • Biovertis AG
    Phone: (43) 1 7989 303
    Campus Vienna Biocenter 6
    Vienna, 1030
    Austria
Advertisement
Advertisement
UsernamePublicRestriction

Register